Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) |
| May 09, 2018 | May 2018 Bond Updates |
|
NEW HAVEN, Conn., May 9, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has established an expanded access program (EAP) with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral sclerosis... |
| View more at: https://www.prnewswire.com/news-releases/biohaven-initiates-expanded-access-program-for-sublingual-bhv-0223-zydis-orally-dissolving-tablets-for-patients-with-amyotrophic-lateral-sclerosis-als-300645113.html |
| Related News |
|